PTPN11 and non-small cell lung carcinoma: In animal models of non-small cell lung cancer (NSCLC), combination of an SHP-2 inhibitor with anti-PD-L1 agents was associated with more pronounced anticancer immune responses and greater efficacy of radiotherapy [48].